ReviewJournal of thrombosis and haemostasis : JTH2015
Venous thrombosis and cancer: from mouse models to clinical trials.
Review in Journal of thrombosis and haemostasis : JTH, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 1 synthesis or guideline pooled it, 121 citations in OpenAlex.
- The Potential Clinical Relevance of Procoagulant Microparticles as Biomarkers of Blood Coagulation in Breast Cancer: A Systematic Review.Asian Pacific journal of cancer prevention : APJCP · 2025Pooled it
- Plasmin promotes hepatocellular carcinoma invasion and metastasis via CXCR4-mediated activation of PI3K/AKT/mTOR signaling.Oncogene · 2026Article
- The role of neutrophils and their immunosuppressive effects on prostate cancer.Histology and histopathology · 2025Review
- Enhanced proteomic profiling of human plasma-derived extracellular vesicles through charge-based fractionation to advance biomarker discovery potential.Journal of extracellular vesicles · 2024Article
- Post-surgery sequelae unrelated to disease progression and chemotherapy revealed in follow-up of patients with stage III colon cancer.EBioMedicine · 2024Article
- Mucin 1 and venous thrombosis in tumor-bearing mice and patients with cancer.Thrombosis research · 2024Article
- Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial.Translational oncology · 2024Article
- Acute Pulmonary Embolism in Oman: A Situational Analysis.Oman medical journal · 2023Article
- Application of the Khorana score for cancer-associated thrombosis prediction in patients of East Asian ethnicity undergoing ambulatory chemotherapy.Thrombosis journal · 2023Article
- Change in cytokine profiles released by mast cells mediated by lung cancer-derived exosome activation may contribute to cancer-associated coagulation disorders.Cell communication and signaling : CCS · 2023Article
- Decreased Platelet Reactivity and Function in a Mouse Model of Human Pancreatic Cancer.Thrombosis and haemostasis · 2023Article
- Circulating Tumor Cells and Cancer-Associated Venous Thrombosis: A Missing Link.Arteriosclerosis, thrombosis, and vascular biology · 2023Article
- Discovery of protein biomarkers for venous thromboembolism in non-small cell lung cancer patients through data-independent acquisition mass spectrometry.Frontiers in oncology · 2023Article
- Safe and effective treatment of venous Thromboembolism associated with Cancer: focus on direct Oral Anticoagulants in Asian patients.Experimental hematology & oncology · 2022Review
- Prognostic value of plasma D-dimer levels in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a retrospective study.Journal of thoracic disease · 2022Article
- Venous thromboembolism and radiation therapy: The final radiation-induced thrombosis study analysis.Cancer medicine · 2022Observational
- Impact of Neutrophil Extracellular Traps on Thrombosis Formation: New Findings and Future Perspective.Frontiers in cellular and infection microbiology · 2022Review
- Extracellular Vesicles Linking Inflammation, Cancer and Thrombotic Risks.Frontiers in cell and developmental biology · 2022Review
- What molecular imaging of cancer patients can teach us about COVID-19.European physical journal plus · 2022Review
- Neutrophil Extracellular Traps (NETs) and Hypercoagulability in Plasma Cell Dyscrasias-Is This Phenomenon Worthy of Exploration?Journal of clinical medicine · 2021Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 3 countries.
Funding
Abstract
Cancer patients have a ~4 fold increased risk of venous thromboembolism (VTE) compared with the general population and this is associated with significant morbidity and mortality. This review summarizes our current knowledge of VTE and cancer, from mouse models to clinical studies. Notably, the risk of VTE varies depending on the type and stage of cancer. For instance, pancreatic and brain cancer patients have a higher risk of VTE than breast and prostate cancer patients. Moreover, patients with metastatic disease have a higher risk than those with localized tumors. Tumor-derived procoagulant factors and growth factors may directly and indirectly enhance VTE. For example, increased levels of circulating tumor-derived, tissue factor-positive microvesicles may trigger VTE. In a mouse model of ovarian cancer, tumor-derived IL-6 and hepatic thrombopoietin have been linked to increased platelet production and thrombosis. In addition, mouse models of mammary and lung cancer showed that tumor-derived granulocyte colony-stimulating factor causes neutrophilia and activation of neutrophils. Activated neutrophils can release neutrophil extracellular traps (NETs) that enhance thrombosis. Cell-free DNA in the blood derived from cancer cells, NETs and treatment with cytotoxic drugs can activate the clotting cascade. These studies suggest that there are multiple mechanisms for VTE in patients with different types of cancer. Preventing and treating VTE in cancer patients is challenging; the current recommendations are to use low-molecular-weight heparin. Understanding the underlying mechanisms may allow the development of new therapies to safely prevent VTE in cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.